Last updated: August 1, 2026
PediaPred is an oral prednisolone sodium phosphate solution used primarily in pediatric patients when systemic corticosteroid treatment is required. The product is an established corticosteroid formulation rather than a new clinical-stage asset. No publicly identifiable PediaPred-specific Phase 2 or Phase 3 development program drives its current commercial position. Clinical evidence largely supports the active ingredient, prednisolone, across inflammatory, allergic, respiratory, rheumatologic, and hematologic conditions.
PediaPred’s commercial outlook is constrained by generic competition, low formulation complexity, limited patent protection, and the availability of competing prednisolone liquids and corticosteroid products. Its value is concentrated in pediatric prescribing, palatability, dosing convenience, pharmacy availability, and institutional supply contracts.
What is PediaPred and which active ingredient does it contain?
PediaPred contains prednisolone sodium phosphate, a water-soluble corticosteroid prodrug that is converted to prednisolone after administration. It is supplied as an oral solution, making it suitable for children and patients who cannot swallow tablets.
The product is used when systemic glucocorticoid therapy is clinically appropriate. Label-supported or commonly accepted uses for prednisolone products include:
- Severe or persistent asthma exacerbations
- Allergic and inflammatory disorders
- Rheumatic disease
- Dermatologic conditions
- Hematologic disorders
- Nephrotic syndrome
- Certain respiratory and autoimmune conditions
Prednisolone sodium phosphate oral solution is pharmacologically distinct from prednisone tablets but is closely related therapeutically. Clinicians select it based on the patient’s age, ability to swallow, dose flexibility, taste, formulation availability, and treatment duration.
The FDA labeling for PediaPred emphasizes that corticosteroids can suppress immune function, alter glucose metabolism, affect growth and bone health, and cause adrenal suppression with prolonged or repeated use (U.S. Food and Drug Administration [FDA], n.d.-a).
What clinical trials support PediaPred?
Are there active clinical trials for PediaPred?
Public clinical-trial databases do not identify a major brand-specific PediaPred development program. The product is an established prescription medicine, so new studies generally evaluate prednisolone or prednisolone sodium phosphate as an active ingredient rather than PediaPred as a branded product.
The clinical-trial profile has three segments:
| Evidence segment |
Relevance to PediaPred |
Commercial significance |
| Historical corticosteroid trials |
Establish efficacy and safety of systemic prednisolone |
Supports continued standard-of-care use |
| Disease-specific prednisolone trials |
Evaluate dosing in asthma, nephrotic syndrome, inflammatory disease, and other conditions |
May influence prescribing and guidelines |
| Pediatric formulation studies |
Assess palatability, dosing, adherence, and pharmacokinetics |
Supports oral-solution positioning |
ClinicalTrials.gov contains studies involving prednisolone in pediatric respiratory disease, nephrotic syndrome, inflammatory disorders, and other indications. These studies generally do not create proprietary rights for PediaPred because prednisolone is an established active ingredient and many studies are investigator-sponsored or evaluate generic formulations (National Library of Medicine, n.d.).
What is the clinical evidence for pediatric use?
Prednisolone remains a widely used systemic corticosteroid in children. Its strongest practical use cases are acute treatment courses in conditions such as asthma and croup-related inflammatory disease, along with longer treatment protocols for nephrotic syndrome and immune-mediated disorders.
Clinical value depends on dose and treatment duration. Short courses are generally associated with lower cumulative toxicity than chronic therapy. Repeated or prolonged exposure can produce:
- Adrenal-axis suppression
- Growth retardation
- Cushingoid features
- Hypertension
- Hyperglycemia
- Mood and behavioral changes
- Increased infection risk
- Osteoporosis and impaired bone development
PediaPred’s oral-liquid format has a clinical advantage where precise weight-based dosing is required. That advantage is practical rather than strongly proprietary. Competing prednisolone solutions can provide similar dosing flexibility if they have comparable concentration, taste, stability, and supply.
What FDA regulatory status does PediaPred have?
PediaPred is an FDA-approved prescription oral solution containing prednisolone sodium phosphate. The product is regulated as a conventional small-molecule drug, not as a biologic.
Its regulatory profile has several implications:
- Biosimilar regulation does not apply.
- Generic competition can proceed through the Abbreviated New Drug Application pathway.
- FDA approval depends on pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and product specifications.
- Clinical efficacy trials are generally not required for every generic entrant.
The relevant FDA regulatory framework includes the product label, the Orange Book listing, drug-safety communications, and any manufacturer-specific application records. The FDA label remains the primary source for dosing, contraindications, warnings, pediatric use, and adverse reactions (FDA, n.d.-a).
What patents protect PediaPred?
Does PediaPred have meaningful active patent protection?
PediaPred is unlikely to have a commercially meaningful active patent estate covering the prednisolone sodium phosphate molecule. Prednisolone is an old corticosteroid, and the product’s principal competitive characteristics arise from the oral-solution formulation and brand distribution rather than new chemical entity protection.
Potential intellectual-property categories include:
| IP category |
Likely relevance to PediaPred |
Generic-entry impact |
| Active ingredient patent |
Prednisolone sodium phosphate is established technology |
Minimal |
| Formulation patent |
Could cover excipients, taste masking, stability, or concentration |
Usually limited if narrow or expired |
| Manufacturing patent |
Could cover preparation or packaging methods |
Low unless difficult to design around |
| Method-of-use patent |
Could cover a specific disease or dosing method |
Limited for broad established uses |
| Trademark |
Protects the PediaPred name and branding |
Does not block generic approval |
The key regulatory question is whether current Orange Book listings include any unexpired patent or exclusivity entry associated with the relevant PediaPred application. FDA Orange Book records should be checked by product name, active ingredient, dosage form, strength, and application holder because patent listings can vary by application and may not cover all generic formulations (FDA, n.d.-b).
What is the Orange Book status of PediaPred?
The Orange Book identifies approved drug products, therapeutic-equivalence evaluations, and certain listed patents and exclusivity rights. For an established prednisolone sodium phosphate oral solution, the likely competitive structure is an approved reference product followed by therapeutically equivalent generic oral solutions.
A product-level Orange Book review should examine:
- Prednisolone sodium phosphate as the active ingredient
- Oral solution dosage form
- Each listed strength
- Reference listed drug status
- Therapeutic-equivalence codes
- Any patent-use-code entries
- Any unexpired pediatric, orphan, or other exclusivity
- Application-holder changes and marketing status
PediaPred’s commercial risk is higher if multiple AB-rated generic products are available. Pharmacy substitution can then occur without prescriber intervention in many jurisdictions, subject to state law and payer policy.
When does PediaPred lose exclusivity?
PediaPred’s principal exclusivity risk is not a near-term patent cliff associated with a new molecular entity. The product is an established corticosteroid formulation with generic-substitution exposure.
The practical exclusivity timeline is:
| Exclusivity element |
Status relevant to PediaPred |
| New chemical entity exclusivity |
Not applicable to an old prednisolone product |
| Five-year new-drug exclusivity |
Not applicable to the active ingredient |
| Three-year clinical-investigation exclusivity |
Unlikely to be commercially relevant |
| Orphan-drug exclusivity |
Not a general PediaPred protection |
| Pediatric exclusivity |
Requires a qualifying FDA request and award; no assumption should be made without an FDA record |
| Patent exclusivity |
Product- and application-specific; must be confirmed in the current Orange Book |
| Trademark exclusivity |
Continues independently but does not prevent generic substitution |
The most important commercial question is therefore not a future patent-expiration date. It is the number of approved generic products, their supply reliability, and the payer’s preference for branded versus generic oral solution.
Are there Paragraph IV challenges to PediaPred?
A Paragraph IV challenge is relevant only if an ANDA applicant alleges that a listed patent is invalid, unenforceable, or not infringed. For an old prednisolone oral solution, Paragraph IV litigation is less likely to determine market entry than ordinary generic approval and therapeutic-equivalence substitution.
No major, widely reported PediaPred Paragraph IV litigation is a central feature of the product’s current market profile. A complete litigation assessment requires review of:
- FDA Paragraph IV notice records
- Federal district court complaints
- ANDA litigation dockets
- Orange Book patent listings
- Settlement agreements
- FDA approval dates for competing ANDAs
If a listed formulation patent exists, a generic applicant could pursue a Paragraph IV route. If no blocking patent remains, the applicant could rely on a Paragraph III certification or avoid patent certification issues altogether.
What formulations are protected by PediaPred?
PediaPred’s principal formulation attributes are:
- Oral liquid delivery
- Prednisolone sodium phosphate as the active ingredient
- Pediatric-appropriate dosing
- Concentration flexibility
- Liquid excipients and preservatives
- Packaging designed for repeated dosing
Formulation differentiation can arise from taste, viscosity, sedimentation control, chemical stability, dosing-device compatibility, preservative selection, and storage requirements. These characteristics can support brand retention but rarely create a durable barrier unless protected by enforceable claims or supported by a clear clinical adherence advantage.
Generic manufacturers can generally develop alternative excipient systems if they preserve pharmaceutical performance and meet FDA requirements. A formulation patent would need claims broad enough to prevent design-around while remaining valid in view of prior art.
Which companies compete with PediaPred?
PediaPred competes within a fragmented market that includes:
- Generic prednisolone sodium phosphate oral solutions
- Prednisolone acetate oral formulations where available
- Prednisone tablets and liquid products
- Dexamethasone oral solutions
- Methylprednisolone tablets or liquid preparations
- Compounded corticosteroid liquids
The most direct competitors are manufacturers of therapeutically equivalent prednisolone sodium phosphate oral solutions. Competitive differentiation typically depends on:
| Factor |
Effect on market position |
| Wholesale acquisition cost |
Determines payer and pharmacy preference |
| Generic availability |
Drives substitution |
| Product concentration |
Affects dosing volume |
| Taste and palatability |
Influences pediatric adherence |
| Supply continuity |
Important during respiratory-virus surges |
| Packaging and dosing syringe |
Supports dispensing convenience |
| Distribution coverage |
Determines pharmacy access |
| Reimbursement status |
Affects branded demand |
PediaPred is more exposed to generic erosion than injectable or complex-delivery corticosteroids because oral solution manufacturing is comparatively accessible and the active ingredient is well established.
What is the market size and revenue outlook for PediaPred?
Public filings generally do not provide standalone PediaPred revenue. The product is not typically reported as a separate growth asset by major pharmaceutical companies, and market-research estimates for the broader prednisolone or pediatric corticosteroid segment cannot be attributed directly to PediaPred.
A defensible projection must separate:
- The total pediatric systemic corticosteroid market
- The oral prednisolone solution segment
- The PediaPred brand
- Generic prednisolone sodium phosphate products
- Institutional and retail channels
A scenario framework is more appropriate than a single unsupported revenue estimate:
| Scenario |
Market trajectory |
PediaPred implication |
| Base case |
Stable or modestly declining unit demand; continued generic substitution |
Brand revenue declines gradually |
| Downside case |
Additional low-cost entrants and supply normalization |
Accelerated volume and price erosion |
| Upside case |
Supply shortages, stronger distribution, or pediatric adherence differentiation |
Temporary share recovery |
| Institutional case |
Contract wins with hospitals or health systems |
Volume growth with lower net pricing |
Demand should remain relatively resilient because corticosteroids are inexpensive, widely used, and clinically established. Brand pricing power should remain weak unless PediaPred has a distribution, supply, or formulation advantage that competitors cannot match.
What generic launch risks exist for PediaPred?
Generic launch risk is high relative to the product’s likely remaining brand value. The main risks are:
- Approval of additional ANDAs
- AB-rated substitution
- Lower generic acquisition cost
- Payer exclusion of the branded product
- Pharmacy inventory rationalization
- Prescriber preference for available generic liquids
- Compounding substitution during shortages
- Loss of shelf space and wholesaler support
A generic entrant does not need to reproduce the PediaPred brand identity. It needs to meet FDA standards for pharmaceutical equivalence and bioequivalence and maintain reliable manufacturing and distribution.
The largest operational risk may be supply disruption rather than patent litigation. Pediatric liquid medicines can experience shortages because of manufacturing constraints, packaging capacity, raw-material interruptions, or sudden seasonal demand. A supplier with reliable inventory can gain temporary share even without durable intellectual-property protection.
How strong is the PediaPred patent estate?
PediaPred’s patent estate appears weak as a long-term exclusivity platform. The active ingredient is old, the dosage form is conventional, and generic substitution is technically feasible. Any surviving protection would most likely relate to a narrow formulation, manufacturing process, package, or specific method of use.
| Patent-strength factor |
Assessment |
| Chemical composition |
Weak |
| Broad formulation protection |
Limited or unlikely for an established product |
| Manufacturing barrier |
Low to moderate |
| Clinical differentiation |
Limited |
| Generic design-around difficulty |
Low |
| Litigation leverage |
Low unless a specific unexpired patent exists |
| Geographic protection |
Primarily jurisdiction-specific and likely limited |
Key Takeaways
- PediaPred is an established prednisolone sodium phosphate oral solution, not a new clinical-stage drug.
- Public clinical development is centered on prednisolone and disease-specific uses, not on a PediaPred-branded pipeline.
- The product’s main value is pediatric liquid dosing, availability, and familiarity.
- Patent-based exclusivity is likely weak compared with products protected by new chemical entity or complex formulation patents.
- Generic and compounded alternatives create substantial substitution risk.
- No major PediaPred-specific Paragraph IV litigation is a defining commercial issue.
- Standalone PediaPred revenue is generally not publicly disclosed.
- The most credible market outlook is stable clinical demand combined with declining branded pricing and share pressure.
- Manufacturing reliability, taste, concentration, distribution, and reimbursement are more important than patent strength.
FAQs About PediaPred Patent and Market Risks
Is PediaPred the same as prednisone?
No. PediaPred contains prednisolone sodium phosphate. Prednisone is a related corticosteroid that is converted to prednisolone in the body. The products have overlapping uses but different active ingredients and formulations.
Is PediaPred available as a generic?
Generic prednisolone sodium phosphate oral solutions may compete with the branded product, depending on current FDA approvals, marketing status, strength, and therapeutic-equivalence listings.
Does PediaPred have biosimilar competition?
No. Biosimilars apply to biologic products. PediaPred is a conventional small-molecule corticosteroid and faces generic-drug competition instead.
Can pharmacies substitute a generic for PediaPred?
Substitution depends on the generic’s FDA therapeutic-equivalence rating, state pharmacy law, payer rules, and the prescriber’s instructions. An AB-rated generic is generally eligible for substitution under applicable law.
What is the largest commercial risk for PediaPred?
The largest risk is sustained generic price and volume erosion, compounded by pharmacy substitution and the limited clinical differentiation of an established oral corticosteroid solution.
References
-
National Library of Medicine. (n.d.). ClinicalTrials.gov: Search results for prednisolone. https://clinicaltrials.gov/search?term=prednisolone
-
U.S. Food and Drug Administration. (n.d.-a). PediaPred prescribing information. FDA labeling database.
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
